Genflow Biosciences PLC Announces Holding(s) in Company - 2
Genflow Biosciences PLC (GENFF) has reported a significant change in shareholding. Jonathan Mark Swann from Rickmansworth, UK, has increased his voting rights in the company from 5.03% to 6.01%, representing 21,025,000 voting rights. The threshold was crossed on January 10, 2025, and the company was notified on January 13, 2025.
The notification indicates this change resulted from an acquisition of voting rights, with all shares being held directly. No financial instruments or similar economic instruments were reported as part of this holding. The shareholder is not controlled by any natural person or legal entity and does not control any other undertaking holding interests in Genflow Biosciences.
Genflow Biosciences PLC (GENFF) ha riportato un cambiamento significativo nella composizione azionaria. Jonathan Mark Swann di Rickmansworth, Regno Unito, ha aumentato i suoi diritti di voto nella società dal 5,03% al 6,01%, corrispondente a 21.025.000 diritti di voto. La soglia è stata superata il 10 gennaio 2025 e la società è stata informata il 13 gennaio 2025.
La notifica indica che questo cambiamento è avvenuto a seguito di un'acquisizione di diritti di voto, con tutte le azioni detenute direttamente. Non sono stati segnalati strumenti finanziari o strumenti economici simili come parte di questa partecipazione. L'azionista non è controllato da alcuna persona fisica o giuridica e non controlla alcun'altra entità che detenga interessi in Genflow Biosciences.
Genflow Biosciences PLC (GENFF) ha informado de un cambio significativo en la participación accionarial. Jonathan Mark Swann de Rickmansworth, Reino Unido, ha incrementado sus derechos de voto en la empresa del 5,03% al 6,01%, lo que representa 21.025.000 derechos de voto. El umbral se superó el 10 de enero de 2025 y la empresa fue notificada el 13 de enero de 2025.
La notificación indica que este cambio se produjo como resultado de una adquisición de derechos de voto, con todas las acciones mantenidas directamente. No se informaron instrumentos financieros ni instrumentos económicos similares como parte de esta participación. El accionista no está controlado por ninguna persona física o entidad jurídica y no controla ninguna otra empresa que posea intereses en Genflow Biosciences.
Genflow Biosciences PLC (GENFF)는 주주 구성에 중요한 변화를 보고했습니다. 영국 리크먼스워스 출신의 Jonathan Mark Swann은 회사에서의 투표권을 5.03%에서 6.01%로 증가시켜 21,025,000개의 투표권을 보유하게 되었습니다. 이 기준은 2025년 1월 10일에 초과되었으며, 회사는 2025년 1월 13일에 통보를 받았습니다.
통보에 따르면, 이번 변화는 모든 주식이 직접 보유됨에 따라 투표권의 인수로 인해 발생했습니다. 이 보유와 관련해 금융 상품이나 유사한 경제적 상품은 보고되지 않았습니다. 주주는 자연인이나 법인에 의해 통제받지 않으며, Genflow Biosciences에 대한 이해관계를 보유한 다른 기업도 통제하지 않습니다.
Genflow Biosciences PLC (GENFF) a signalé un changement significatif dans l'actionnariat. Jonathan Mark Swann de Rickmansworth, Royaume-Uni, a augmenté ses droits de vote dans l'entreprise de 5,03 % à 6,01 %, représentant 21 025 000 droits de vote. Le seuil a été franchi le 10 janvier 2025, et l'entreprise a été informée le 13 janvier 2025.
La notification indique que ce changement résulte d'une acquisition de droits de vote, toutes les actions étant détenues directement. Aucun instrument financier ou économique similaire n'a été signalé dans le cadre de cette participation. L'actionnaire n'est contrôlé par aucune personne physique ou entité juridique et ne contrôle pas une autre structure détenant des intérêts dans Genflow Biosciences.
Genflow Biosciences PLC (GENFF) hat eine signifikante Veränderung in der Aktionärsstruktur gemeldet. Jonathan Mark Swann aus Rickmansworth, Großbritannien, hat seine Stimmrechte im Unternehmen von 5,03% auf 6,01% erhöht, was 21.025.000 Stimmrechten entspricht. Die Schwelle wurde am 10. Januar 2025 überschritten, und das Unternehmen wurde am 13. Januar 2025 benachrichtigt.
Die Benachrichtigung zeigt, dass diese Änderung das Ergebnis eines Erwerbs von Stimmrechten war, wobei alle Aktien direkt gehalten werden. Es wurden keine finanziellen Instrumente oder ähnliche wirtschaftliche Instrumente im Rahmen dieses Anteils gemeldet. Der Aktionär wird von keiner natürlichen oder juristischen Person kontrolliert und kontrolliert auch kein anderes Unternehmen, das Interessen an Genflow Biosciences hält.
- Increased institutional ownership with single investor raising stake above 6%
- None.
TR-1: Standard form for notification of major holdings
LONDON, UNITED KINGDOM / ACCESSWIRE / January 13, 2025 /
1. Issuer Details
ISIN
GB00BP2C3V08
Issuer Name
GENFLOW BIOSCIENCES PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Jonathan Mark Swann
City of registered office (if applicable)
rickmansworth
Country of registered office (if applicable)
United Kingdom
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
10-Jan-2025
6. Date on which Issuer notified
13-Jan-2025
7. Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer |
Resulting situation on the date on which threshold was crossed or reached | 6.010000 | 0.000000 | 6.010000 | 21025000 |
Position of previous notification (if applicable) | 5.030000 | 0.000000 | 5.030000 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
GB00BP2C3V08 | 21025000 | 0 | 6.010000 | 0.000000 |
Sub Total 8.A | 21025000 | |||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
|
|
|
|
|
Sub Total 8.B1 |
|
|
| |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
| ||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
|
|
|
|
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
none
12. Date of Completion
13-Jan-2025
13. Place Of Completion
London
View the original press release on accesswire.com
FAQ
What is the new ownership percentage of Jonathan Swann in GENFF as of January 2025?
How much did Jonathan Swann's ownership in GENFF increase from the previous position?
When did GENFF report this change in shareholding?
Does Jonathan Swann hold any financial instruments in GENFF besides direct shares?
